

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09/863,054</u>	Prepared by <u>ewc</u>	Tracking Number <u>05974895</u>	
Examiner-GAU <u>Wortman</u>	Date <u>8/27/04</u>	Week Date <u>7-05-04</u>	
<u>1648</u>	No. of queries <u>-1-</u>	IFW	

JACKET			
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION	MESSAGE
a. Page Missing	<u>Substitute Sequence Listing per</u> <u>amendment 3-18-04 is not in file</u> <u>Please advise</u> <u>Thank you</u> <u>ewc</u>
b. Text Continuity	
c. Holes through Data	
d. Other Missing Text	
e. Illegible Text	
f. Duplicate Text	
g. Brief Description	
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
<b>CLAIMS</b>	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	
d. Incorrect Numbering	
e. Index Disagrees	
f. Punctuation	
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials
	<b>RESPONSE</b>
	initials

remaining three patients (A-9, A-10, A-13) displayed a variant sequence in which the carboxy-terminal valine was substituted by alanine at position 357. Among the patients infected by the prototype virus, CTL responders and nonresponders to HBsAg<sub>348-357</sub> were observed, just as for the response to BsAg<sub>335-343</sub>. On the other hand, none of the 3 patients infected by the variant virus displayed a CTL response to the prototype peptide.--

Please replace the paragraph beginning at page 40, line 26, with the following:

--An HBsAg<sub>335-343</sub> specific CTL line (patient A-1) and an HBsAg<sub>348-357</sub> specific CTL line (patient A-4) were generated by stimulation with peptide sequences WLSLLVPFV (SEQ ID NO:10) and GLSPTVWLSV (SEQ ID NO:26), respectively. CTL were incubated with <sup>51</sup>Cr-labelled JY target cells that had been preincubated either with media, with the inducing peptide or (in the case of HBsAg<sub>348-357</sub>) with a variant peptide (GLSPTVWLSA (SEQ ID NO:57)). CTL were also incubated with <sup>51</sup>Cr-labelled JY target cells that had been infected with a panel of 6 recombinant vaccinia viruses that express the HBV major (V-HBs), middle (V-preS2), and large (V-preS1) envelope polypeptides derived from ayw and adw HBV genomes. Wild-type vaccinia viruses (V-wt) were used as controls. The HBsAg<sub>335-343</sub> specific CTL line (right panel) was used at an E:T=40:1. The HBsAg<sub>348-357</sub> specific CTL line (left panel) was used at an E:T=3:1. Results shown represent % lysis in a 4 hour <sup>51</sup>Cr release assay.--

Please cancel the present "SEQUENCE LISTING", pages 42-49, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 18, at the end of the application. Cancel the page numbers for the Claims and Abstract and renumber as pages 42-44, accordingly.